SiBionics shared new findings about the use of AI in continuous glucose monitor (CGM) technologies. The China-based company shared new perspectives on AI at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. It outlined how AI can extend the value of CGM technology beyond just monitoring. SiBionics develops the […]
Clinical Trials
Senseonics reports sustained year-long CGM implant outcomes, insulin pump integration benefits
Senseonics (Nasdaq:SENS) announced new data from a real-world study demonstrating the sustained performance of its Eversense 365 CGM. Real-world evidence demonstrated the long-term performance and positive impact of the world’s first year-long continuous glucose monitor (CGM). The company shared findings at the 19th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Barcelona. […]
Afon Technology highlights accuracy of non-invasive blood glucose monitor
Afon Technology says that its Glucowear non-invasive blood glucose monitor demonstrated significant accuracy in its first trial. The Monmouthshire, UK-based company says its device achieved approximately 75% overall accuracy in distinguishing between normal and elevated blood glucose levels in the initial evaluation of the technology. CEO Sabih Chaudhry wore the device, testing it during his […]
Abbott study highlights better glucose outcomes with Libre CGM in type 2 diabetes on basal insulin
Abbott (NYSE:ABT) today announced results from a trial demonstrating better glucose outcomes for users of continuous glucose monitors (CGMs). The FreeDM2 randomized controlled trial evaluated whether real-time CGM can help people with type 2 diabetes using basal insulin improve their glucose management. It took place across 24 clinical sites in the UK, evaluating 303 participants. […]
Abbott data highlights burden of diabetic ketoacidosis
Abbott (NYSE:ABT) today announced new real-world data highlighting the growing global burden of diabetic ketoacidosis (DKA). DKA occurs when ketones build up in the blood to dangerous levels. According to Abbott, DKA is a leading cause of death for people under 58 with type 1 diabetes. While traditionally associated with type 1, it’s also increasingly […]
Insulet shares study outcomes supporting fully closed-loop insulin pump for type 2 diabetes
Insulet (Nasdaq:PODD) today shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes. The maker of the Omnipod 5 — the world’s first available tubeless, wearable, automated insulin delivery system — said during a 2025 Investor Day event that it plans to bring its first fully closed-loop system […]
Airiver Medical wins FDA breakthrough nod for drug-coated balloon, treats first patient
Airiver Medical announced today that it received FDA breakthrough device designation for its pulmonary drug-coated balloon (DCB). Additionally, Airiver announced the first treated patients in a clinical trial for the DCB. The Brooklyn Park, Minnesota-based company designed its DCB to treat central airway stenosis. Central airway stenosis (airway narrowing) can lead to prolonged intubation, tracheostomy, […]
Sava Technologies reports first clinical evidence for CGM biosensor
Sava Technologies today announced the first 10-day clinical evidence for its microsensor-based continuous glucose monitor (CGM). London-based Sava completed an independent clinical study of 46 participants with type 1 and insulin-dependent type 2 diabetes. The study took place across sites in Oxford and Cambridge, UK. It demonstrated reliable glucose measurement using Sava’s proprietary microsensor technology […]
MannKind enrolls first patient in study of inhaled insulin for pediatric type 1 diabetes
MannKind (Nasdaq:MNKD) announced today that it enrolled the first patient in the INHALE-1ST study of its Afrezza inhaled insulin. INHALE-1ST evaluates the initiation of Afrezza inhalation powder therapy shortly after type 1 diabetes diagnosis in pediatric patients. Afrezza (insulin human) inhalation powder is a fast-acting insulin formulation delivered through an inhaler device. MannKind engineered the mechanical […]
Medtronic touts time in range outcomes with MiniMed 780G
Medtronic (NYSE:MDT) today announced a new real-world retrospective analysis highlighting positive outcomes with its MiniMed 780G. The medtech giant’s Diabetes business, which recently took the next step toward becoming a standalone public company called MiniMed through an IPO, said MiniMed 780G achieved American Diabetes Association (ADA)-recommended goals for time-in-range (TIR), even on days when mealtime […]
